Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

DD Bowtell, S Böhm, AA Ahmed, PJ Aspuria… - Nature reviews …, 2015 - nature.com
High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths,
and overall survival has not changed significantly for several decades. In this Opinion article …

The biological and therapeutic relevance of mRNA translation in cancer

SP Blagden, AE Willis - Nature reviews Clinical oncology, 2011 - nature.com
Protein synthesis is a tightly regulated process that enables post-transcriptional control of
gene expression. Dysregulation of this process is associated with the development and …

[HTML][HTML] The La-related proteins, a family with connections to cancer

C Stavraka, S Blagden - Biomolecules, 2015 - mdpi.com
The evolutionarily-conserved La-related protein (LARP) family currently comprises Genuine
La, LARP1, LARP1b, LARP4, LARP4b, LARP6 and LARP7. Emerging evidence suggests …

[HTML][HTML] Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free …

AR Clamp, EC James, IA McNeish, A Dean, JW Kim… - The Lancet, 2019 - thelancet.com
Background Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-
line chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a …

La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs

RM Lahr, BD Fonseca, GE Ciotti, HA Al-Ashtal, JJ Jia… - Elife, 2017 - elifesciences.org
The 5'terminal oligopyrimidine (5'TOP) motif is a cis-regulatory RNA element located
immediately downstream of the 7-methylguanosine [m7G] cap of TOP mRNAs, which …

Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies

D Olmos, D Barker, R Sharma, AT Brunetto, TA Yap… - Clinical cancer …, 2011 - AACR
Purpose: GSK461364 is an ATP-competitive inhibitor of polo-like kinase 1 (Plk1). A phase I
study of two schedules of intravenous GSK461364 was conducted. Experimental Design …

Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in …

M Slusarczyk, MH Lopez, J Balzarini… - Journal of medicinal …, 2014 - ACS Publications
Gemcitabine is a nucleoside analogue commonly used in cancer therapy but with limited
efficacy due to a high susceptibility to cancer cell resistance. The addition of a …

The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration

C Burrows, N Abd Latip, SJ Lam… - Nucleic acids …, 2010 - academic.oup.com
The RNA binding protein Larp1 was originally shown to be involved in spermatogenesis,
embryogenesis and cell-cycle progression in Drosophila. Our data show that mammalian …

The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer

TG Hopkins, M Mura, HA Al-Ashtal… - Nucleic acids …, 2016 - academic.oup.com
RNA-binding proteins (RBPs) are increasingly identified as post-transcriptional drivers of
cancer progression. The RBP LARP1 is an mRNA stability regulator, and elevated …

A study of symptoms described by ovarian cancer survivors

C Stavraka, A Ford, S Ghaem-Maghami, T Crook… - Gynecologic …, 2012 - Elsevier
OBJECTIVE: A cross-sectional, observational study to evaluate physical and psychological
symptoms experienced by patients following completion of treatment for ovarian cancer and …